The revenue for CTX-130 is expected to reach an annual total of $24 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

CTX-130 Overview

CTX-130 is under development for the treatment of hematologic malignancies such as certain lymphomas and solid tumors such as relapsed or refractory metastatic renal cell carcinoma. The therapeutic candidate consists of allogeneic T cells engineered to express chimeric antigen receptors (CAR T-cells), relapsed or refractory T or B cell malignancies including diffuse large B-cell lymphoma (DLBCL), mycosis fungoides and sezary syndrome (MF/SS). It acts by targeting CD70 expressing cancer cells. It is developed based on CRISPR’s gene-editing technology. It is administered by intravenous route.

CRISPR Therapeutics Overview

CRISPR Therapeutics (CRISPR) is a gene editing company. It focuses on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a gene-editing technology that modifies, deletes, or corrects disease-causing abnormalities at its genetic sources. Its major development programs include ex vivo programs involving gene editing of hematopoietic cells; ex vivo programs in immuno-oncology; in vivo programs targeting the liver and additional in vivo programs targeting other organ systems including muscle and lung. It has research and development operations in Cambridge, Massachusetts, the US and business operations in London, the UK. CRISPR is headquartered in Zug, Switzerland.
The company reported revenues of (US Dollars) US$1.2 million for the fiscal year ended December 2022 (FY2022), a decrease of 99.9% over FY2021. The operating loss of the company was US$673.2 million in FY2022, compared to an operating profit of US$373.5 million in FY2021. The net loss of the company was US$650.2 million in FY2022, compared to a net profit of US$377.7 million in FY2021.

For a complete picture of CTX-130’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 18 March 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.